QualityDipStocks / Health Care · Pharmaceuticals
Ionis Pharmaceuticals IONS
Outside our quality screen, so we don’t track its dips. It’s 52% below its 52-week high.
Outside our quality screen, 17% under its Market Value. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Deepest drop from a 52-week high in over 3 years
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $49.82price −17%
- Off 52-wk high
- −52%
- Risk vs market
- Lowbeta 0.56
5 bullish · 5 bearish See why
Repriced or dip?
Repricing: business changed
The price is 52% below its 52-week high (Feb 6), but the business held up: shares outstanding fewer shares, each owns more.
Some numbers held up (shares outstanding fewer shares, each owns more), others slipped (revenue −9.6%, revenue growth rate −27.8 pts, operating margin −39.2 pts). The price is 52% below its 52-week high.
The price is 52% below its 52-week high, and the business changed too: revenue −9.6%, revenue growth rate −27.8 pts, operating margin −39.2 pts.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 6 numbers, high vs now
- Revenue, last 12 months$967M → $874M (−9.6%)changed
- Revenue growth rate+20.4% → −7.4% a year (−27.8 pts)changed
- Operating margin−28.8% → −68.0% (−39.2 pts)changed
- Shares outstanding−8.2% (fewer shares, each owns more)held up
- Stock vs its sector (Health Care)stock −52%, sector median +18% since Feb 6changed
- Price fall vs business numbersprice −52%, revenue/EPS/FCF median −10% (shown, not scored)
Business numbers as reported at the high (12 months to Sep 30, 2025) vs the latest filing (12 months to Jun 30, 2026). Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for IONS: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much IONS moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 3.3× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.56
- Volatility
- 43% vs 13% SPY
- Correlation SPY
- 0.17
- Correlation QQQ
- 0.10
How it ranks
Where IONS stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 4 measures
- Free cash flow yield−8.1% · free cash flow vs market capLowest 4%of 1,391
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months−7.4% · vs the 12 months beforeLowest 4%of 1,814
- Operating margin−68% · of sales kept as operating profitLowest 1%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $49.82
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
Cash returnsShare count down 9.3% in a year.
GrowthSales compounded 17% a year from FY2022 to FY2025.
ProfitabilityOperating margin widened to −40.4% in FY2025 from −44.9% in FY2023 (SEC filings).
ProfitabilityGross margin of 98%, above the 62% median for the 146 Health Care companies we cover.
ValuationTrades 17.2% below its Market Value of $49.82, the average price paid since the Jul 29 filing.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$561M over the last 12 months), so there’s no cash-flow value under the price.
Balance sheetOperating income covers interest only -31.6× over the last 12 months.
GrowthSales growth slowed to −7% over the last 12 months, from 17% a year over the prior three fiscal years.
ProfitabilityLost $565M over the last 12 months (net income, SEC filings).
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; sales down vs the year-ago quarter; debt load unclear or high.
All fundamentals
FCF yield -8.1% · ROE -105% · Sales −7%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −8.1%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 7.89×
- Price / book
- 15.69×
- Market cap
- $6.9Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $874M
- Sales growth, 12 months
- −7.4%vs the 12 months before
- Sales growth, 3 yrs
- +17.1%/yrfrom FY2022
- Diluted EPS, 12 months
- −$3.48
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$565M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 98.2%
- Operating margin
- −68.0%
- Net margin
- −64.7%
- FCF margin
- −64.2%
- Return on equity
- −105%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $2.1B
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- -31.6×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- −$561M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- −9.3%diluted shares vs a year ago
- Stock-based comp
- $163M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Ionis Pharmaceuticals’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.6B · Sales −41%
- Free cash flow, 12 months−$0.6B
- Free-cash-flow yield-8.1%
- Gross margin−7%
- Operating margin−38%
- Return on invested capital−50%
- Return on equity−106%
- Sales growth (latest quarter vs year-ago quarter)−41%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $41.24
- PriceMon Nov 2 close$41.24you are here
- 52-wk lowlowest close, 1 year$41.24at the price
- Market Valueavg paid since Jul 29$49.82+20.8%
- 52-wk highhighest close, 1 year$86.50+109.7%
Momentum & 52-week range
RSI 36 · 5 days −5.0%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 4
- DateWed Nov 4
- Consensus EPS($1.22)
- Year-ago EPS($0.80)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
IONS is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Ionis Pharmaceuticals in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.